Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.

The journal of supportive oncology

Volumn 1, Issue 2, 2003, Pages 131-138

  Vadhan Raj, Saroj ^a   Mirtsching, Barry ^a   Charu, Veena ^a   Terry, Dixon ^a   Rossi, Gregory ^a   Tomita, Dianne ^a   McGuire, William P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; SICKNESS IMPACT PROFILE; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, HYPOCHROMIC; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FATIGUE; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOPLASMS; SICKNESS IMPACT PROFILE; TIME FACTORS; TREATMENT OUTCOME;

EID: 1542324739     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)